NMRA insider trading
NasdaqGS HealthcareNeumora Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Company website: www.neumoratx.com
NMRA insider activity at a glance
FilingIQ tracks 145 insider transactions for NMRA in filings since Sep 18, 2023. The most recent transaction is dated Aug 21, 2026.
Across the full history, 44 open-market purchases
and 32 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NMRA insider trades is 44.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NMRA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding NMRA
Frequently asked
- How many insider trades does FilingIQ track for NMRA?
- FilingIQ tracks 145 Form 4 insider transactions for NMRA (Neumora Therapeutics, Inc.), covering filings from Sep 18, 2023 onwards. 27 of those are dated within the last 90 days.
- Are NMRA insiders net buyers or net sellers?
- Across the full Form 4 history for NMRA, 44 transactions (30%) were open-market purchases and 32 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NMRA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is NMRA in?
- Neumora Therapeutics, Inc. (NMRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $591.39M.
Methodology & sources
Every NMRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.